Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Altimmune Inc (NASDAQ: ALT) was $4.14 for the day, up 6.15% from the previous closing price of $3.9. In other words, the price has increased by $6.15 from its previous closing price. On the day, 6.85 million shares were traded. ALT stock price reached its highest trading level at $4.44 during the session, while it also had its lowest trading level at $3.95.
Ratios:
Our analysis of ALT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.18 and its Current Ratio is at 17.18. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
On January 08, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $18.Stifel initiated its Buy rating on January 08, 2025, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 22 ’25 when Durso Jerome Benedict bought 12,500 shares for $4.13 per share. The transaction valued at 51,569 led to the insider holds 12,500 shares of the business.
Sohn Catherine A. bought 1,000 shares of ALT for $5,784 on Mar 17 ’25. The Director now owns 1,000 shares after completing the transaction at $5.78 per share. On Mar 13 ’25, another insider, WEAVER GREGORY L, who serves as the Chief Financial Officer of the company, bought 10,000 shares for $5.20 each. As a result, the insider paid 51,996 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALT now has a Market Capitalization of 431977440 and an Enterprise Value of 236741280. For the stock, the TTM Price-to-Sale (P/S) ratio is 21599.00 while its Price-to-Book (P/B) ratio in mrq is 2.13. Its current Enterprise Value per Revenue stands at 11837.064 whereas that against EBITDA is -2.62.
Stock Price History:
The Beta on a monthly basis for ALT is 0.03, which has changed by -0.48344374 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, ALT has reached a high of $8.75, while it has fallen to a 52-week low of $2.90. The 50-Day Moving Average of the stock is -7.91%, while the 200-Day Moving Average is calculated to be -10.84%.
Shares Statistics:
ALT traded an average of 3.43M shares per day over the past three months and 5942050 shares per day over the past ten days. A total of 104.34M shares are outstanding, with a floating share count of 103.63M. Insiders hold about 0.68% of the company’s shares, while institutions hold 40.02% stake in the company. Shares short for ALT as of 1764288000 were 23157756 with a Short Ratio of 6.75, compared to 1761868800 on 21780366. Therefore, it implies a Short% of Shares Outstanding of 23157756 and a Short% of Float of 22.33.
Earnings Estimates
The dynamic stock of Altimmune Inc (ALT) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.22 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.94 and -$1.04 for the fiscal current year, implying an average EPS of -$0.98. EPS for the following year is -$1.34, with 7.0 analysts recommending between -$1.03 and -$1.82.
